Publications

2025

Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer

The Journal of Clinical Investigation

First author: Palomeque JA.

Corresponding authors: Celià-Terrassa T.

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response

Translational Oncology

First author: López-Velasco JI.

Corresponding authors: Caffarel MM., Urruticoechea A.

2024

Cytokine-centered strategies to boost cancer immunotherapy

Molecular Oncology

First author: Manzano S.

Corresponding authors: Manzano S., Caffarel MM.

A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer

Breast Cancer Research

First author: López-Velazco JI.

Corresponding authors: Caffarel MM., Urruticoechea A.

Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER(+) breast cancer

Science Translational Medicine

First author: Bacci M.

Corresponding authors: Morandi A.

Preventing alpelisib-related hyperglycaemia in HR+/HER2-/ PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

eClinicalMedicine

First author: Llombart-Cussac A.

Corresponding authors: Llombart-Cussac A.

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

Nature Medicine

First author: Hiensch AE.

Corresponding authors: May AM.

Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer

International Journal of Molecular Science

First author: Nemours S.

Corresponding authors: Lawrie CH.

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study

Breast

First author: Cortés A.

Corresponding authors: Llombart-Cussac A.

Dormancy-inducing 3D engineered matrix uncovers mechanosensitive and drug-protective FHL2-p21 signaling axis

Science Advances

First author: Bakhshandeh S. and Heras U.

Corresponding authors: Cipitria A.